Immunoassay Industry News Update

The report "Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Western Blot), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Laboratories)—Global Forecast to 2030", is projected to reach USD 47.7 billion by 2030 from USD 35.5 billion in 2025, at a CAGR of 6.1% during the forecast period.

Browse 570 market data tables and 65 figures spread through 492 pages and in-depth TOC on the “Immunoassay Market- Global Forecast To 2030.”
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/immunoassay-market-436.html

The growth of the immunoassay market is mainly driven by several key factors. One of the leading causes is the expanding elderly population, which is closely connected to a rising incidence of chronic and age-related diseases like cancer, diabetes, and heart conditions. This demographic change has increased the demand for early, accurate, and efficient diagnostic tools, where immunoassays play an essential role. Additionally, emerging markets offer new growth opportunities, fueled by increasing R&D investments in these regions, thereby improving the environment for market players.

By product, the reagents & kits segment accounted for the largest immunoassay product market share in 2024.

The immunoassay market, by product, is segmented into reagents & kits and analyzers. In 2024, the reagents and kits segment held the largest market share. This significant share is mainly due to the recurring use of reagents and kits across diagnostic workflows. Unlike analyzers, which are a one-time capital investment used over several years, reagents and kits are consumed with each test, making them essential for daily operations in both centralized labs and decentralized testing environments. These consumables are vital for maintaining the continuity and scalability of testing services, especially in high-throughput laboratories and clinical settings. Their role in supporting diverse immunoassay platforms across applications like infectious diseases, endocrinology, and oncology has further cemented their market dominance.

In 2024, ELISA accounted for the largest share in the immunoassay technology market.

Based on technology, the immunoassay market is segmented into ELISA, CLIA, IFA, rapid tests, ELISpot, western blotting, and other technologies. In 2024, ELISA (enzyme-linked immunosorbent assay) held the largest market share. ELISA's dominance comes from its versatile diagnostic uses, especially in infectious disease and cancer screening, where high sensitivity and specificity are crucial. Its strong standardization, compatibility with high-throughput automation, and cost-effectiveness have made ELISA a preferred choice in clinical laboratories. Additionally, ongoing improvements in ELISA-based assay design and integration with digital result interpretation systems are improving diagnostic accuracy and workflow efficiency, reinforcing its leadership in the field.

In 2024, the hospitals & clinics held the largest market share in the immunoassay end user market.

By end user, the immunoassay market is segmented into hospitals & clinics, clinical laboratories, blood banks, and home care settings. In 2024, hospitals and clinics held the largest market share. This is mainly because they play a central role in performing most diagnostic tests, especially for acute and chronic conditions that need quick and reliable results. Hospitals are often equipped with advanced immunoassay platforms capable of handling complex diagnostic panels and large patient volumes. Additionally, their integration with emergency care, specialized departments, and surgical units makes them a key hub for immunoassay-based diagnostics. As hospitals increasingly adopt automated and multiplexed immunoassay systems to improve turnaround time and diagnostic accuracy, their demand for high-performance testing solutions continues to fuel growth in this segment.

By region, North America accounted for the largest regional market share in 2024.

In 2024, North America led the immunoassay market mainly because of its strong presence of established diagnostic companies and advanced healthcare infrastructure. The US was a key contributor to this regional leadership, driven by high demand for sophisticated immunoassay-based diagnostics in both clinical and research settings. This demand is heavily influenced by the increasing prevalence of chronic and infectious diseases, along with the widespread use of automated and point-of-care immunoassay platforms. Furthermore, collaborations between regulatory agencies and national research organizations have boosted innovation and improved quality standards in diagnostic testing. For example, partnerships involving the Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration (FDA) have resulted in the creation of standardized immunoassay guidelines and reference materials. These joint efforts have enhanced assay validation, traceability, and consistency of results, increasing confidence in test performance. Such strategic initiatives not only ensure regulatory compliance but also support the quick adoption of new immunoassay technologies in hospitals, labs, and public health programs across North America. Consequently, the region remains a hub for technological innovation, regulatory leadership, and market adoption in the global immunoassay industry.

Some of the leading players in the market include Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher (US), Revvity (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A. (Italy), and Bio- Rad Laboratories, Inc. (US).

Don’t miss out on business opportunities in Immunoassay Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/